Skip to main content

Table 1 Clinicopathological characteristics of patients with breast cancer who were diagnosed with ductal carcinoma in situ and invasive ductal carcinoma

From: Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma

Characteristics Ductal carcinoma in situ
(n = 199)
Invasive ductal carcinoma
(n = 914)
P value
Mean age (years, ±SD) 50.1 ± 9.4 49.3 ± 9.9 0.649
Mean body mass index (kg/m2, ± SD) 23.2 ± 3.0 23.4 ± 3.2 0.745
History of bilateral breast cancer (n, %) 14 (7.0) 30 (3.3) 0.014
Clinical tumor size on ultrasound (cm, ± SD) 2.01 ± 1.7 2.0 ± 1.2 0.213
Pathological tumor size (cm, ± SD) 2.2 ± 1.9 1.7 ± 1.1 0.109
Estrogen receptor, positive (n, %) 135 (67.8) 639 (69.9) 0.379
Progesterone receptor, positive (n, %) 120 (60.3) 568 (62.1) 0.136
c-erbB2 protein, positive (n, %) 73 (36.7) 169 (18.5) 0.226
Triple-negative breast cancer (n, %) 11 (5.5) 85 (9.3) 0.002
Adjuvant chemotherapy (n, %) 0 460 (50.3) <  0.001
Adjuvant radiotherapy (n, %) 67 (33.7) 636 (69.6) < 0.001
Adjuvant hormonal therapy (n, %) 125 (62.8) 687 (75.2) 0.061
Follow-up period (mo, ± SD) 90.1 ± 25.3 88.6 ± 19.1 0.241
Locoregional recurrence (n, %) 3 (1.5) 17 (1.9) 0.506
Distant metastasis (n, %) 1 (0.5) 24 (2.6) < 0.001
Death (n, %) 1 (0.5) 9 (1.0) 0.192